Thursday, March 28, 2024
Advertisement
  1. You Are At:
  2. News
  3. India
  4. Delhi NCR: Russian COVID-19 vaccine 'Sputnik V' roll-out delayed again

Delhi NCR: Russian COVID-19 vaccine 'Sputnik V' roll-out delayed again

The roll-out of Russian COVID-19 vaccine 'Sputnik V' at various private hospitals in the Delhi-NCR region has been delayed again

PTI Edited by: PTI New Delhi Published on: June 27, 2021 13:21 IST
sputnik v
Image Source : PTI

The roll-out of Russian COVID-19 vaccine 'Sputnik V' at various private hospitals in the Delhi-NCR region has been delayed again

The roll-out of Russian COVID-19 vaccine 'Sputnik V' at various private hospitals in the Delhi-NCR region has been delayed again, officials said on Sunday. "We do not have a clarity on the dates of the vaccine roll-out," a spokesman of Apollo Hospitals said.

Indraprastha Apollo here had earlier said that it would tentatively start administering the two-dose vaccine by June 25.

An official of Madhukar Rainbow Children's Hospital said the facility has also not received Sputnik V doses so far from Hyderabad-based Dr Reddy's Laboratories, the marketing partner for the vaccine in the country. 

"There is a delay on the part of the suppliers. They have not shared any specific reason for it. I think it could be related to the supply of both the doses together," he said. Sputnik V uses two different viruses that cause the common cold (adenovirus) in humans. The two doses, given 21 days apart, are different and not interchangeable.

Fortis Healthcare, which had said that it would make Sputnik V available at its Gurgaon and Mohali hospitals, has also not started administering the Russian vaccine to people so far.

The Centre has fixed the price of the vaccine at Rs 1,145 per dose. The maximum price of Covishield for private COVID-19 Vaccination Centres (CVCs) has been fixed at RS 780 per dose, while that of Covaxin at Rs 1,410 per dose.

Russia's Gamaleya National Research Institute of Epidemiology and Microbiology has developed the vaccine and the Russian Direct Investment Fund (RDIF) is marketing it globally. Dr Reddy's Laboratories has been importing the shots from Russia. Over a period of time, the vaccine is also going to be manufactured in India.  According to Gamaleya and the RDIF, Sputnik V has demonstrated an efficacy rate of 92 per cent.

Also Read: COVID-19: Sputnik V roll out delayed in Delhi

Also Read: Sputnik V to offer booster shot to other manufacturers, adjusted to work against Delta variant

Advertisement

Read all the Breaking News Live on indiatvnews.com and Get Latest English News & Updates from India

Advertisement
Advertisement
Advertisement
Advertisement